You are here

Share:

Search Technologies

Showing 41-55 of 55 results found

Polymeric Delivery Platform for Therapeutics

The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.

Processes for Producing and Purifying Nucleic Acid-Containing Compositions

This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.

Renal Selective Unsaturated Englerin Analogues

Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.

RNASEH-Assisted Detection Assay for RNA

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.

Scytovirin Domain 1 Related Polypeptides

Researchers at the NCI seek licensing for novel anti-HIV peptide therapeutics. The researchers developed novel proteins for HIV inhibition. Scytovirin is a potent anti-HIV protein with two domains having strong symmetry. NCI researchers produced a much smaller, functional, scytovirin domain polypeptide – SD1 – for use as a HIV therapeutic.

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Researchers at the National Cancer Institute (NCI) have developed single domain human CD4 proteins to inhibit HIV-1 entry and improved human domain antibodies against HIV-1. Fusion proteins comprising the single domain CD4 and HIV-1 antibody can be used to effectively neutralize HIV-1 in vitro. Researchers seek licensing for development of these antibody-based therapeutics for the treatment of HIV-1.

Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase

Researchers at the National Cancer Institute discovered small-molecule compounds containing 1-hydroxy-2-oxo-1,8-naphthyridine moieties whose activity against HIV-1 integrase mutants confer resistance to currently approved INSTIs. Preliminary rodent efficacy, metabolic, and pharmacokinetic studies have been completed by the NCI researchers. The National Cancer Institute seeks partners to commercialize this class of compounds through licensing or co-development.

Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles

Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.

Targeted RNA/DNA Nanoparticles with Single Stranded RNA Toeholds

The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.

The Biospecimen Pre-analytical Variables (BPV) Program

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.

Treating JC Polyomavirus Infection and Associated Leukoencephalopathy

The National Cancer Institute seeks parties interested in collaborative research to co-develop or license methods of treating disorders related to polyomavirus, as well as vaccines for patients undergoing immunosuppressive treatment such as multiple sclerosis, rheumatoid arthritis, B cell cancers, and Crohn’s disease.

Vaccines for HIV

The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development. Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV. Two major hurdles to overcome are immunodominance and sequence diversity. This vaccine utilizes a strategy for overcoming these two issues by identifying the conserved regions of the virus and exploiting them for use in a targeted therapy. NCI seeks licensees and/or research collaborators to commercialize this technology, which has been validated in macaque models.

Virus-Like Particles That Can Deliver Proteins and RNA

The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.

Pages